Development of a synthetic cannabinoid program

这项研究建议涉及开发一个完全合成的化学平台来获取大麻二酚(CBD)。CBD是大麻树脂中的一种次要成分，不具精神活性和不成瘾。CBD有越来越多的治疗应用，例如在偏头痛和神经性疼痛等疼痛治疗以及癫痫和癫痫的治疗中。虽然天然大麻树脂预计将于2018年10月17日取消生产计划，但获得合成CBD可以缓解不断增长的大麻行业面临的许多问题(成本、水平不一致、真菌和虫害等)。可靠的CBD合成途径将允许可靠地生产和制备类似物，从而能够彻底调查这种非阿片类止痛剂的疼痛控制适应症。

This research proposal is concerned with the development of a totally synthetic chemical platform to access cannabidiol (CBD). CBD is a minor constituent in cannabis (Cannabis sativa) resin and is non-psychoactive and non-addictive. CBD has a growing list of therapeutic applications, for example in pain management such as migraine and neuropathic pain, as well as treatment of epilepsy and seizures. While natural cannabis resin is expected to be descheduled on October 17th 2018, access to synthetic CBD alleviates many of the problems (cost, inconsistent levels, fungal and insect infestations etc) faced in the growing cannabis industry. Reliable synthetic access to CBD will allow for reliable production and preparation of analogs that will permit a thorough investigation into the pain-management indications of this non-opiate based analgesic.